Browsing Tag
Hercules Capital
3 posts
Replimune Group (NASDAQ: REPL) plans layoffs after FDA rejects Tudriqev again, forcing a biotech reset
Replimune plans layoffs after the FDA rejected Tudriqev again. Read what the setback means for REPL stock, cash runway, strategy, and rivals.
Behavox expands AI ecosystem with acquisition of Mosaic Smart Data
Behavox, a leading AI-driven insights company, has completed the acquisition of Mosaic Smart Data, a financial technology firm…
BridgeBio Pharma secures $299m in funding to accelerate genetic disease drug development
BridgeBio Pharma, a leading clinical-stage biopharma company specialising in treatments for genetic diseases, has raised $299.2 million in…